Clinical Trials Logo

Clinical Trial Summary

The study is aimed at assessing the clinical follow-up and the outcomes of pregnancies exposed to ella, whether due to failure of the emergency contraception or inadvertent exposure during pregnancy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01569737
Study type Observational
Source HRA Pharma
Contact
Status Completed
Phase
Start date November 18, 2014
Completion date June 29, 2018

See also
  Status Clinical Trial Phase
Completed NCT00271583 - Efficacy Trial of CDB 2914 for Emergency Contraception Phase 2/Phase 3
Completed NCT00777556 - Emergency Contraception Actual Use Study Phase 3
Completed NCT00677755 - Medical Abortion for Emergency Contraception Failure N/A
Recruiting NCT06162611 - Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo Phase 4
Completed NCT00411684 - Safety and Efficacy of CDB-2914 for Emergency Contraception Phase 3
Completed NCT03208985 - A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions Phase 3
Completed NCT02078414 - Continued Use of Effective Contraception After Use of Emergency Contraception
Completed NCT01569113 - Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo. Phase 4
Completed NCT01963962 - Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception N/A
Recruiting NCT03120728 - Application for the Etonogestrel/Ethinyl Estradiol Ring Phase 4
Active, not recruiting NCT02076217 - Quick Start of Highly Effective Contraception
Not yet recruiting NCT04172584 - Awareness & Use of Emergency Contraception
Completed NCT03395756 - Depot Medroxyprogesterone Acetate as Emergency Contraception Early Phase 1
Completed NCT03614494 - Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception Phase 2/Phase 3